AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9657538 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 71
Study 9657538 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10-20 mg
Number of subjects: 71
Study 8210017 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anaesthesia (SA)
Number of subjects: 20
Study 8210017 — intervention group
Group type: COMPARATOR
Intervention: General anaesthetic (GA)
Number of subjects: 20
Study 2690898 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclic estrogen/gestagen (n = 20)
Number of subjects: 37
Study 2690898 — intervention group
Group type: COMPARATOR
Intervention: Oral calcium (2000 mg elemental calcium per day) (n = 17)
Number of subjects: 37
Study 31005917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 160
Study 31005917 — intervention group
Group type: COMPARATOR
Intervention: Flat shoe inserts
Number of subjects: 160
Study 28314486 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin provision (IP) therapy
Number of subjects: 2368
Study 28314486 — intervention group
Group type: COMPARATOR
Intervention: Insulin sensitizing (IS) therapy
Number of subjects: 2368
Study 25283522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1,500 mg
Number of subjects: 32
Study 25283522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1,500 mg (single infusion)
Number of subjects: 32
Study 25283522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levetiracetam 1,500 mg (repeated infusion)
Number of subjects: 32
Study 23701193 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 400 μg
Number of subjects: 60
Study 23701193 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 60
Study 21707217 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing
Number of subjects: 0
Study 21707217 — intervention group
Group type: COMPARATOR
Intervention: Restudying
Number of subjects: 0
Study 19632624 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 98
Study 19632624 — intervention group
Group type: COMPARATOR
Intervention: Minimal ventricular pacing
Number of subjects: 98
Study 16220495 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity score‐based multiple imputation (MI) method
Number of subjects: 0
Study 16220495 — intervention group
Group type: COMPARATOR
Intervention: Generalized estimating equations (GEE) method
Number of subjects: 0
Study 16220495 — intervention group
Group type: COMPARATOR
Intervention: Complete-case (CC) method
Number of subjects: 0
Study 15383187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (dose titration to achieve LDL-C and non-HDL-C goals)
Number of subjects: 0
Study 15383187 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 15383187 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment (dose titration)
Number of subjects: 0
Study 12185636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A intake
Number of subjects: 47
Study 12185636 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotenoid levels
Number of subjects: 47
Study 12185636 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol levels
Number of subjects: 47
Study 12185636 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric evaluation and bone age
Number of subjects: 47
Study 9868840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero-cell rabies vaccine (PVRV, Verorab) according to the 2-1-1 schedule
Number of subjects: 0
Study 9868840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero-cell rabies vaccine (PVRV) plus equine rabies immunoglobulins (ERIG, 40 IU/kg body weight) according to the 2-1-1 schedule
Number of subjects: 0
Study 9868840 — intervention group
Group type: EXPERIMENTAL
Intervention: Vero-cell rabies vaccine (PVRV) plus human rabies immunoglobulins (HRIG, 20 IU/kg body weight) according to the 2-1-1 schedule
Number of subjects: 0
Study 8091167 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days with N-acetylcysteine (NAC) 2 x 600 mg bid (d 21‐30)
Number of subjects: 34
Study 8091167 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (OME) 40 mg bid and Amoxicillin (AMOX) 750 mg tid for 10 days without N-acetylcysteine (NAC)
Number of subjects: 34
Study 2691409 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-s cycling sprint test
Number of subjects: 9
Study 2691409 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000-m time trial
Number of subjects: 9
Study 2691409 — intervention group
Group type: COMPARATOR
Intervention: 30-s, 40-s, and 60-s cycling sprint tests
Number of subjects: 9
Study 1130178 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 (2,000 IU daily) for 3 months
Number of subjects: 25
Study 1130178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 1130178 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D or placebo (normal children)
Number of subjects: 25
Study 30576525 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zaleplon
Number of subjects: 34
Study 30576525 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zolpidem
Number of subjects: 34
Study 30576525 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 34
Study 30576525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29171827 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach
Number of subjects: 30
Study 29171827 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 30
Study 29171827 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 30
Study 26198857 — intervention group
Group type: EXPERIMENTAL
Intervention: Metomidate Hydrochloride
Number of subjects: 0
Study 26198857 — intervention group
Group type: EXPERIMENTAL
Intervention: MS‐222
Number of subjects: 0
Study 26198857 — intervention group
Group type: COMPARATOR
Intervention: Nonanesthetized fish
Number of subjects: 0
Study 23897903 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) combined with physical training (PT)
Number of subjects: 9
Study 23897903 — intervention group
Group type: COMPARATOR
Intervention: Physical training (PT) without tDCS
Number of subjects: 9
Study 21765069 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of IPTp-SP (n = 413)
Number of subjects: 814
Study 21765069 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of IPTp-SP (n = 401)
Number of subjects: 814
Study 19015207 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 200 mg plus methotrexate (MTX)
Number of subjects: 619
Study 19015207 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol 400 mg plus methotrexate (MTX)
Number of subjects: 619
Study 19015207 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 619
Study 16759926 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 IU weekly increments of rFSH
Number of subjects: 158
Study 16759926 — intervention group
Group type: COMPARATOR
Intervention: 50 IU weekly increments of rFSH
Number of subjects: 158
Study 15295244 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (up to 0.3 mg/kg, n = 7)
Number of subjects: 61
Study 15295244 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (up to 0.4 mg/kg, n = 17)
Number of subjects: 61
Study 15295244 — intervention group
Group type: COMPARATOR
Intervention: Pentobarbital (up to 5 mg/kg, n = 33)
Number of subjects: 61
Study 15295244 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 61
Study 11699053 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (1,142.0 +/- 79.64 microg/d for at least 12 months)
Number of subjects: 65
Study 11699053 — intervention group
Group type: COMPARATOR
Intervention: Control group (no corticosteroids for at least 1 year)
Number of subjects: 65
Study 11699053 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate
Number of subjects: 65
Study 11699053 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 9159976 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural hearing tactics
Number of subjects: 19
Study 9159976 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 19
Study 7960188 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures applicable to 14 patients with complete spermatogenesis and distal obstruction of the excurrent ducts.
Number of subjects: 102
Study 7960188 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 102
Study 30315901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (0.5, 1.25, or 5 mg/day)
Number of subjects: 27528
Study 30315901 — intervention group
Group type: COMPARATOR
Intervention: Placebo or intramuscular interferon beta‐1a (IFNβ‐1a IM)
Number of subjects: 27528
Study 27928888 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care tools plus limited telephone support
Number of subjects: 80
Study 27928888 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention/usual care
Number of subjects: 80
Study 26154700 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting local anesthetic (bupivacaine hydrochloride, 0.50%)
Number of subjects: 99
Study 26154700 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 99
Study 23257173 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day)
Number of subjects: 14
Study 23257173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 21318442 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine injection
Number of subjects: 42
Study 21318442 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 42
Study 18496062 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin flushes (1:100 dilution)
Number of subjects: 88
Study 18496062 — intervention group
Group type: EXPERIMENTAL
Intervention: Splints
Number of subjects: 88
Study 18496062 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age, wrist and scalp insertions, and 24-gauge catheters
Number of subjects: 88
Study 16517117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dean‐Woodcock Sensory‐Motor Battery (DWSMB)
Number of subjects: 500
Study 12706129 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition enriched with glutamine (0.7 g kg(‐1)day(‐1))
Number of subjects: 25
Study 12706129 — intervention group
Group type: COMPARATOR
Intervention: Isonitrogenous control
Number of subjects: 25
Study 10910450 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued MMF treatment (2 g b.i.d.) in group A, n=22
Number of subjects: 48
Study 10910450 — intervention group
Group type: COMPARATOR
Intervention: Switching to AZA treatment (1 mg/kg) in group B, n=26
Number of subjects: 48
Study 10910450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 48
Study 8731618 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patches
Number of subjects: 1686
Study 1569341 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg twice a day for 3 days
Number of subjects: 38
Study 1569341 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (standard course)
Number of subjects: 38
Study 2866073 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-208 5 mg
Number of subjects: 10
Study 2866073 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-208 10 mg
Number of subjects: 10
Study 2866073 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-208 20 mg
Number of subjects: 10
Study 2866073 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 10
Study 2866073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31478796 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 84
Study 31478796 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual-advice
Number of subjects: 84
Study 31478796 — intervention group
Group type: COMPARATOR
Intervention: Control (no advice)
Number of subjects: 84
Study 28952607 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mcg/day of vitamin K2 (menaquinone-7, MK-7)
Number of subjects: 214
Study 28952607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 27456837 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples calls (CC)
Number of subjects: 280
Study 27456837 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual calls (IC)
Number of subjects: 280
Study 27456837 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes education (DE)
Number of subjects: 280
Study 25379541 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric prilocaine + fentanyl
Number of subjects: 50
Study 25379541 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine + fentanyl
Number of subjects: 50
Study 22487663 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (morphine, ketorolac, and butylscopolammonium bromide)
Number of subjects: 89
Study 22487663 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (morphine and ketorolac)
Number of subjects: 89
Study 20190331 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from predominantly central sleep apnoea (CSA) to predominantly obstructive sleep apnoea (OSA)
Number of subjects: 98
Study 20190331 — intervention group
Group type: COMPARATOR
Intervention: Nonconversion group (remained predominantly CSA)
Number of subjects: 98
Study 20190331 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from CSA to OSA
Number of subjects: 98
Study 16519928 — intervention group
Group type: EXPERIMENTAL
Intervention: Light conducting inserts
Number of subjects: 60
Study 16519928 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (incremental technique)
Number of subjects: 60
Study 16519928 — intervention group
Group type: COMPARATOR
Intervention: Inactive inserts
Number of subjects: 60
Study 16519928 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (single increment)
Number of subjects: 60
Study 16324616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 124
Study 16324616 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 124
Study 12216965 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg/day
Number of subjects: 445
Study 12216965 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 2,400 mg/day
Number of subjects: 445
Study 12216965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 12216965 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 445
Study 9470014 — intervention group
Group type: EXPERIMENTAL
Intervention: Prick skin tests using a battery of food antigens
Number of subjects: 165
Study 9470014 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenges
Number of subjects: 165
Study 9470014 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening prick skin tests for seven foods (milk, egg, peanut, soy, wheat, cod/catfish, cashew)
Number of subjects: 165
Study 7648766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg (S)-ketamine
Number of subjects: 5
Study 7648766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg (S)-ketamine
Number of subjects: 5
Study 7648766 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg (S)-ketamine (control)
Number of subjects: 5
Study 2608196 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic gonadotropin
Number of subjects: 0
Study 2608196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 0
Study 2608196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovariostatics
Number of subjects: 0
Study 2608196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation inducers
Number of subjects: 0
Study 1009523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (1000 mg/m2 every 3 weeks) iv
Number of subjects: 443
Study 1009523 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (700 mg/m2 every 3 weeks) iv plus CCNU (70 mg/m2 every 6 weeks) orally
Number of subjects: 443
Study 1009523 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination regimen
Number of subjects: 443
Study 1009523 — intervention group
Group type: COMPARATOR
Intervention: Single agent (Cyclophosphamide)
Number of subjects: 443
Study 31983658 — intervention group
Group type: EXPERIMENTAL
Intervention: Ataluren
Number of subjects: 279
Study 31983658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 31271068 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone (MCI-186)
Number of subjects: 67
Study 27787467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise (10 × 1 minute at 100% of maximal treadmill velocity with 1 minute recovery)
Number of subjects: 21
Study 27787467 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 21
Study 27787467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval exercise
Number of subjects: 21
Study 25835516 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience Corps intervention
Number of subjects: 111
Study 25835516 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 24219758 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic exercise program (PICO) for 3 months
Number of subjects: 50
Study 24219758 — intervention group
Group type: COMPARATOR
Intervention: Educational attention (control group)
Number of subjects: 50
Study 21357641 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 64
Study 21357641 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 64
Study 19291601 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-slice CT with 80 cc CM at 5 cc/sec followed by a 50 cc saline chaser bolus containing 20% contrast media
Number of subjects: 97
Study 19291601 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual source CT with a CM protocol adapted for scan time and identical saline/CM chaser bolus
Number of subjects: 97
Study 19291601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both 64-slice and dual source CT using a 20% saline chaser bolus
Number of subjects: 97
Study 19291601 — intervention group
Group type: EXPERIMENTAL
Intervention: CM protocol adapted for scan time
Number of subjects: 97
Study 17290009 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 31
Study 17290009 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (low dose)
Number of subjects: 31
Study 17290009 — intervention group
Group type: COMPARATOR
Intervention: L-NMMA (high dose)
Number of subjects: 31
Study 15344451 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature selection method for shape-based classification
Number of subjects: 0
Study 11129924 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised, behavioural approach to rehabilitation
Number of subjects: 0
Study 11129924 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific nursing interventions
Number of subjects: 0
Study 9105060 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐1078 (pranlukast), 450 mg twice daily
Number of subjects: 79
Study 9105060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 1443452 — intervention group
Group type: EXPERIMENTAL
Intervention: Native Parietaria product
Number of subjects: 24
Study 1443452 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Parietaria product
Number of subjects: 24
Study 1443452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1443452 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated groups (Native and Modified Parietaria)
Number of subjects: 24
Study 3954918 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 3954918 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 0
Study 29959285 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making (SDM) training
Number of subjects: 31
Study 28631682 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional therapy combined with homeovox
Number of subjects: 40
Study 28631682 — intervention group
Group type: COMPARATOR
Intervention: Traditional therapy alone
Number of subjects: 40
Study 26508659 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine treatment for 6 months
Number of subjects: 38
Study 24594076 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50-100mg daily for 2 days
Number of subjects: 6
Study 21945457 — intervention group
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation (iTBS)
Number of subjects: 21
Study 21945457 — intervention group
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation (cTBS)
Number of subjects: 21
Study 21945457 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DOPA
Number of subjects: 21
Study 21945457 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 21
Study 19388861 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 24
Study 19388861 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture
Number of subjects: 24
Study 19388861 — intervention group
Group type: COMPARATOR
Intervention: Comparison between acupuncture and sham treatment
Number of subjects: 24
Study 18091190 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable
Number of subjects: 323
Study 15126928 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment (nitrendipine 10-40 mg daily, possibly with enalapril 5-20 mg daily, hydrochlorothiazide 12.5-25 mg daily)
Number of subjects: 4695
Study 15126928 — intervention group
Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (placebo)
Number of subjects: 4695
Study 15126928 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antihypertensive treatment
Number of subjects: 4695